Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer
Kosteneffektivitätsanalyse von Cadonilimab plus Chemotherapie als Erstlinientherapie bei HER-2-negativem fortgeschrittenem Magenkrebs
Frontiers in Public Health · 21.07.2025 · 13
DOI: 10.3389/fpubh.2025.1644176 ↗Auf einen Blick
Eine Kosten-Nutzen-Analyse verglich Cadonilimab plus Chemotherapie mit Chemotherapie allein bei HER-2-negativem fortgeschrittenem Magenkrebs in China. Insgesamt war die Kombination laut Autor:innen nicht kosteneffektiv; im Subgruppenstatus PD-L1 CPS ≥ 5 möglicherweise schon.
Fragestellung
Ist Cadonilimab plus Chemotherapie im Vergleich zu Chemotherapie allein bei HER-2-negativem fortgeschrittenem Magenkrebs kosteneffektiv?
Methode
Kosten-Nutzen-Analyse mit partitioniertem Überlebensmodell aus Sicht des chinesischen Gesundheitssystems; 10-Jahres-Zeithorizont; Daten aus Literatur, nationalen Datenbanken und der Phase-3-Studie COMPASSION-15.
Ergebnisse
In der Gesamtpopulation betrug der inkrementelle Nutzen 1,08 QALYs bei Mehrkosten von 58.862,61 USD; ICER 54.502,42 USD pro QALY. Bei PD-L1 CPS ≥ 5: 1,33 QALYs, 35.661,87 USD Mehrkosten; ICER 26.813,44 USD pro QALY.
Einschränkungen
Sensitivitätsanalysen prüften die Robustheit; probabilistische Sensitivitätsanalyse mit 4,70 % bzw. 93,90 % Kosteneffektivitätswahrscheinlichkeit.
Schlussfolgerung der Autor:innen
Die Zugabe von Cadonilimab zur Standardchemotherapie ist insgesamt möglicherweise nicht kosteneffektiv. Bei PD-L1 CPS ≥ 5 könnte die Therapie in China kosteneffektiv sein.
Kernaussagen
- Gesamtpopulation: ICER 54.502,42 USD pro QALY
- PD-L1 CPS ≥ 5: ICER 26.813,44 USD pro QALY
- WTP-Schwelle: 40.343,68 USD pro QALY
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, online erschienen am 21.07.2025. Verfasst von Longfeng Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
This study aims to evaluate the cost-effectiveness of using cadonilimab plus chemotherapy compared to chemotherapy in HER-2-negative advanced gastric cancer from the perspective of the Chinese healthcare system.
Methods
A cost-effectiveness analysis was conducted utilizing a partitioned survival model to simulate the expected costs and outcomes associated with the treatment of patients with cadonilimab in combination with chemotherapy versus chemotherapy over a 10 years lifetime horizon. Cost data were sourced from published literature and national databases. Data on treatment efficacy, adverse events, and transition probabilities were derived from the phase 3 COMPASSION-15 trial. The WTP threshold in this study was established at 40,343.68 USD per QALY. Sensitivity analyses were performed to evaluate the robustness of the results and assess the impact of variations in key parameters on the cost-effectiveness outcomes.
Results
The base case analysis revealed that in all population of randomized patients, treatment with cadonilimab resulted in an incremental gain of 1.08 QALYs compared to chemotherapy, at an incremental cost of 58,862.61 USD. The ICER for this cohort was calculated to be 54,502.42 USD per QALY. In the subgroup of patients with a PD-L1 CPS ≥ 5, patients treated with cadonilimab experienced a greater increase in 1.33 QALYs compared to chemotherapy, at an incremental cost of 35,661.87 USD. The ICER for this subgroup was 26,813.44 USD per QALY. Sensitivity analyses conducted demonstrated the robustness of the results to variations in model inputs and assumptions. Moreover, the probabilistic sensitivity analysis indicated that cadonilimab in combination with chemotherapy had a 4.70 and 93.90% probabilities of being considered cost-effective at a WTP threshold of 40,343.68 USD per QALY for the all randomized patient group and the subgroup of patients with a PD-L1 CPS ≥ 5, respectively.
Conclusion
The addition of cadonilimab to standard chemotherapy for first line treatment of HER-2-negative advanced gastric cancer may not be considered a cost-effective option compared to chemotherapy alone. However, for the subgroup of patients with PD-L1CPS ≥ 5, the ICER was 26,813.44 USD per QALY, indicating that this treatment approach could potentially be deemed cost-effective in China.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.
- Department of Acupuncture and Rehabilitation, Shantou Hospital of Traditional Chinese Medicine, Shantou, China.
- Department of Pharmacy, Cancer Hospital of Shantou University Medical College, Shantou, China.
Zitieren
APA
Zhang, L., Yang, Q., & Zheng, Z. (2025). Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer. Frontiers in Public Health, 13. https://doi.org/10.3389/fpubh.2025.1644176
Vancouver
Zhang L, Yang Q, Zheng Z. Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer. Frontiers in Public Health. 2025;13. doi:10.3389/fpubh.2025.1644176
BibTeX
@article{Zhang2025,
author = {Zhang, Longfeng and Yang, Qingsheng and Zheng, Zhiwei},
title = {Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer},
journal = {Frontiers in Public Health},
year = {2025},
volume = {13},
doi = {10.3389/fpubh.2025.1644176}
}
EUVIMED